Institutions / Baker Bros. Advisors LP / Activity
Activity — Baker Bros. Advisors LP
9 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Exit | Ultragenyx Pharmaceutical Inc. Common stock | $-63.77M | -2.8M -100.00% | 0 | high |
| Q1 2026 as of | Exit | Terns Pharmaceuticals, Inc. Common stock | $-38.38M | -950K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Biocryst Pharmaceuticals Inc Common stock | $-22.02M | -2.8M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Ventyx Biosciences, Inc. Common stock | $-21.21M | -2.3M -100.00% | 0 | medium |
| Q1 2026 as of | Exit | Nuvalent, Inc. Common stock | $-14.48M | -144K -100.00% | 0 | medium |
| Q1 2026 as of | Exit | 4D Molecular Therapeutics, Inc. Common stock | $-3.57M | -476K -100.00% | 0 | low |
| Q1 2026 as of | Exit | Vir Biotechnology, Inc. Common stock | $-3.27M | -543K -100.00% | 0 | low |
| Q1 2026 as of | Exit | 483119202 Common stock | $-1.00M | -1.8M -100.00% | 0 | low |
| Q1 2026 as of | Exit | ACRV Acrivon Therapeutics, Inc. Common Stock | $-55.0K | -23K -100.00% | 0 | low |